Elias Tharakan’s Post

Hot take: when an eClinical vendor says they support decentralized trials, the only follow‑up question that matters is: 𝐖𝐡𝐞𝐫𝐞 𝐢𝐧 𝐲𝐨𝐮𝐫 𝐚𝐫𝐜𝐡𝐢𝐭𝐞𝐜𝐭𝐮𝐫𝐞 𝐝𝐨𝐞𝐬 𝐭𝐡𝐞 𝐰𝐨𝐫𝐝 "𝐫𝐞𝐜𝐨𝐧𝐜𝐢𝐥𝐢𝐚𝐭𝐢𝐨𝐧" 𝐬𝐭𝐢𝐥𝐥 𝐚𝐩𝐩𝐞𝐚𝐫? Because reconciliation is what you do when systems don't agree. Systems don't agree when they're not unified. And when they're not unified, you get: • Five audit trails instead of one • Site coordinators managing five logins instead of one • A database lock that takes twice as long as it should Every major eClinical vendor "supports" DCTs – meaning their platforms can participate in a hybrid study with configuration and integration work. That is not the same as being DCT‑native – designed from the foundation up around: • A unified patient‑centric data model • Real‑time streaming ingestion • Compliance embedded architecturally, not enforced through process The distinction matters because trial data requirements are not going to conform to platform limitations. Digital endpoints. Continuous telemetry. Longitudinal monitoring. The FDA's signals about continuous trials aren't a distant horizon – they are directions of travel. I published the 𝐭𝐡𝐢𝐫𝐝 𝐚𝐧𝐝 𝐟𝐢𝐧𝐚𝐥 𝐩𝐚𝐫𝐭 of my series yesterday – the architecture piece. It covers: • The five layers of a DCT‑native platform • What is genuinely available vs. masked by custom integration • Three questions that reveal the architecture under any vendor's demo 👇 Link to the articles in comments 𝘕𝘰𝘵 𝘦𝘷𝘦𝘳𝘺𝘰𝘯𝘦 𝘸𝘪𝘭𝘭 𝘢𝘨𝘳𝘦𝘦 𝘸𝘪𝘵𝘩 𝘮𝘺 𝘧𝘳𝘢𝘮𝘪𝘯𝘨. 𝘐'𝘥 𝘢𝘤𝘵𝘶𝘢𝘭𝘭𝘺 𝘸𝘦𝘭𝘤𝘰𝘮𝘦 𝘵𝘩𝘦 𝘱𝘶𝘴𝘩𝘣𝘢𝘤𝘬 – 𝘦𝘴𝘱𝘦𝘤𝘪𝘢𝘭𝘭𝘺 𝘧𝘳𝘰𝘮 𝘷𝘦𝘯𝘥𝘰𝘳 𝘵𝘦𝘢𝘮𝘴 𝘸𝘩𝘰 𝘵𝘩𝘪𝘯𝘬 𝘐'𝘷𝘦 𝘨𝘰𝘵𝘵𝘦𝘯 𝘴𝘰𝘮𝘦𝘵𝘩𝘪𝘯𝘨 𝘸𝘳𝘰𝘯𝘨. #eClinical #DCTNative #Reconciliation #UnifiedPlatform #SiteBurden #EventStreaming #DataIntegrity #ClinicalTrials